| Pharmaceutical Information |
| Drug Name |
Copanlisib |
| Drug ID |
BADD_D02544 |
| Description |
Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The drug targets the enzyme that plays a role in regulating cell growth and survival. Copanlisib was granted accelerated approval on September 14, 2017 under the market name Aliqopa for the treatment of adult patients with relapsed follicular lymphoma and a treatment history of at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that is caused by unregulated proliferation and growth of lymphocytes. The active ingredient in Aliquopa intravenous therapy is copanlisib dihydrochloride. |
| Indications and Usage |
Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EM02 |
| DrugBank ID |
DB12483
|
| KEGG ID |
D10867
|
| MeSH ID |
C000589253
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0S5LD
|
| NDC Product Code |
50419-385 |
| UNII |
WI6V529FZ9
|
| Synonyms |
copanlisib | 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide | BAY 80-6946 | Aliqopa |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
1032568-63-0 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
